Printer Friendly


 WOBURN, Mass., Sept. 22 /PRNewswire/ -- Telor Ophthalmic Pharmaceuticals, Inc. (NASDAQ-NMS: TELR) announced today that based on the results of its just-completed Phase IIa clinical trial of TEKRON(TM), the company will revise its program for developing TEKRON for controlling elevated intraocular pressure associated with glaucoma and ocular hypertension. In the clinical trial, the topical formulation of the active ingredient, ethacrynic acid, was associated with eye irritation deemed unacceptable by the company. Telor is evaluating use of proprietary ethacrynic acid analogs currently in preclinical development and modified formulations of the existing compound for its TEKRON program.
 "Rather than proceeding with further clinical trials of the current formulation, we plan to make a decision in the near future regarding the most prudent course for development of an ethacrynic acid analog or an alternative formulation," said Stephen J. Riggi, Ph.D., president and chief executive officer of Telor. "Results of recent preclinical studies in tissue culture and in animals using ethacrynic acid or analogs continue to support the belief that the administration of this class of compounds will increase fluid outflow from the eye and reduce intraocular pressure."
 Dr. Riggi also noted that both the Phase IIa study and the effort to develop analogs of ethacrynic acid are part of a broad program to develop new anti-glaucoma products that control intraocular pressure by increasing fluid outflow from the eye. Telor has identified a number of second generation compounds related to ethacrynic acid and expects to select a lead molecule for product development in the coming months.
 The TEKRON study results have no impact on Telor's ongoing Phase III multicenter trial of XARANO(TM), an intraocular ethacrynic acid formulation for the treatment of acute increases in intraocular pressure following cataract surgery.
 The TEKRON Phase IIa trial studied a topical, once-a-day formulation of ethacrynic acid. The trial, which was conducted at a single center, was double-masked and placebo-controlled.
 Telor is an ophthalmic pharmaceutical company dedicated to the development and marketing of innovative prescription pharmaceuticals for use in the treatment of age-related eye diseases and in ophthalmic surgery. The company's goal is to introduce into the worldwide ophthalmic pharmaceuticals market a broad portfolio of patent-protected products that are based on novel mechanisms of action and that offer significant improvements over existing therapies.
 The company's lead product in clinical development is XARANO, a potential product for use during cataract surgery to prevent or reduce transient post-operative increases in intraocular pressure. In addition, clinical studies are underway to assess the feasibility of a pharmaceutical approach to the treatment of presbyopia, an age-related impairment of the ability of the eye to focus on near objects. Telor has its headquarters in Woburn, Mass.
 -0- 9/22/93
 /CONTACT: Stephen J. Riggi, Ph.D., president & CEO of Telor Ophthalmic Pharmaceuticals, 617-937-0393; or Lynne H. Brum of Feinstein Partners, 617-577-8110 for Telor/

CO: Telor Ophthalmic Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU:

DJ -- NE015A -- 4850 09/22/93 16:16 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 22, 1993
Previous Article:SUIT FILED AGAINST I.I.S.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters